ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1951

Quantitative HRCT Analysis in Sjögren’s Disease-associated ILD: CALIPER-Derived Imaging Biomarkers for Prognostic Assessment

Gaetano La Rocca1, Francesco Ferro2, Vincenzo Uggenti3, Beatrice Dei4, Giovanni Fulvio4, Michele Moretti4, Marta Mosca5, Chiara Romei3 and Chiara Baldini5, 1University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, 2Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, 3University of Pisa, 2nd Radiology Unit, Pisa, Italy, 4Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, 5University of Pisa, Pisa, Pisa, Italy

Meeting: ACR Convergence 2025

Keywords: Bioinformatics, Biomarkers, Imaging, interstitial lung disease, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1936–1971) Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial Lung Disease (ILD) is a frequent manifestation of Sjögren’s Disease (SjD), associated with significant morbidity and mortality. However, data on the prevalence of progressive ILD in SjD remain scarce, and biomarkers for predicting progression are lacking. Computer-Aided Lung Informatics for Pathology Evaluation and Rating (CALIPER) is a validated CT-based software that quantifies ILD patterns such as ground-glass opacities, reticulation, honeycombing, and low attenuation areas. CALIPER-derived parameters correlate with pulmonary function tests (PFT) and outcomes in IPF and other autoimmune ILDs, but their role in SjD-ILD is unexplored.The aim of this study was to assess the prognostic value of CALIPER-derived parameters in SjD-ILD patients

Methods: SjD patients (2016 ACR/EULAR criteria) with HRCT-confirmed ILD followed from Jan 2018 to Sep 2023 were retrospectively included if ≥1 HRCT was suitable for CALIPER analysis. Clinical, lab, respiratory, and PFT data were collected at baseline and follow-up. Progressive fibrosing ILD (PF-ILD) was defined (ATS criteria) by ≥2 of: worsening symptoms, FVC decline ≥5% or DLCO ≥10%, or radiological progression within 1 year. CALIPER-derived ILD% (sum of ground-glass, reticular, honeycombing) and VRS% (vascular-related structures) were calculated. Visual ILD extent (Warrick score) and ILD pattern were assessed by a thoracic radiologist

Results: Twenty-three patients (F:M=18:5, mean age 66.2±9.5 yrs, mean follow-up 6.1±5 yrs) were enrolled. ILD patterns included NSIP (n=14), UIP (n=6), and NSIP+OP (n=3). Dyspnea and cough occurred in 21 and 19 patients, respectively. Median baseline FVC and DLCO were 83% and 64%. Seventeen patients received immunosuppressants; none received antifibrotics. Seven required long-term oxygen (LTO2) and 7 developed PF-ILD. Both baseline ILD% and VRS% demonstrated a moderate to strong correlation with FCV% and DLCO%, visual ILD quantification with Warrick score and between them (table 1). VRS%, Reticulation%, and Honeycombing% were significantly higher in UIP (p=.021, .038, and .047, respectively). On univariate regression analysis, VRS% (OR 3.2, 95%CI 1.1-9.1, p=.03) and ILD% (OR 1.13, 95%CI 1.01-1.3, p=.05) were associated with LTO2 necessity. According to ROC analysis, VRS% had an AUC of 0.813 (p=.019) with an optimal cut-off of 3.8%, yielding a sensitivity of 71.4% and a specificity of 87.5% in predicting LTO2 necessity. ILD% had an AUC of 0.777 (p=.038) with a cut-off of 11.6% resulting in a sensitivity of 71.4% and a specificity of 75% in predicting LTO2 necessity.On univariate regression analysis VRS% (OR 2.8, 95%CI 1-8, p=.05) was associated with a PF-ILD behavior in the next year, with an AUC of 0.85 (p=.023) and an optimal cut-off of 3.8% resulting in a sensitivity of 83.3% and specificity of 80%.

Conclusion: CALIPER-derived parameters correlate strongly with lung function and predict adverse outcomes in SjD-ILD. Automated HRCT analysis offers promising digital biomarkers for disease assessment and risk stratification. Integrating these metrics with clinical and functional data could support early identification of progressive ILD and guide therapy. Further validation in larger cohorts is warranted

Supporting image 1Correlation of CALIPER-derived parameters with functional indices and HRCT visual assessment with Warrick score


Disclosures: G. La Rocca: None; F. Ferro: None; V. Uggenti: None; B. Dei: None; G. Fulvio: None; M. Moretti: None; M. Mosca: AbbVie, 2, AstraZeneca, 2, 6, Biogen, 2, BMS, 2, Eli Lilly, 6, GSK, 2, 5, 6, Idorsia, 2, Milteny, 2, Novartis, 2, Otsuka, 2, 6, UCB, 2, 6; C. Romei: None; C. Baldini: None.

To cite this abstract in AMA style:

La Rocca G, Ferro F, Uggenti V, Dei B, Fulvio G, Moretti M, Mosca M, Romei C, Baldini C. Quantitative HRCT Analysis in Sjögren’s Disease-associated ILD: CALIPER-Derived Imaging Biomarkers for Prognostic Assessment [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/quantitative-hrct-analysis-in-sjogrens-disease-associated-ild-caliper-derived-imaging-biomarkers-for-prognostic-assessment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quantitative-hrct-analysis-in-sjogrens-disease-associated-ild-caliper-derived-imaging-biomarkers-for-prognostic-assessment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology